How To Enhance The Competitiveness Of Pharmaceutical Intermediate Companies
Pharmaceutical intermediates refer to some chemical raw materials or chemical products used in the process of drug synthesis. According to the industry, the pharmaceutical intermediate industry, as an important field of fine chemicals, will have more room for development in the future.
Judging from the development history of my country's pharmaceutical intermediate industry, after nearly 30 years of development, pharmaceutical intermediates have developed from a small branch of the chemical industry to an emerging industry with an output value of several billion yuan, and its market competition has become increasingly fierce.
At present, with the changes in the pharmaceutical market structure and the limited output of new drugs on the market, the development of new products in the pharmaceutical intermediate industry is becoming more and more difficult, the competition of traditional products is becoming more and more fierce, and the profit of the pharmaceutical intermediate industry is declining rapidly In this regard, how to develop pharmaceutical intermediate companies has become a difficult problem that has to be considered.
The industry believes that it may start from the aspects of technology, influence, transformation, etc., to form a company's own competitive advantage, so as to stand out in the market.
In terms of technology, it mainly refers to improving technology and saving costs. It is reported that the process route of pharmaceutical intermediates is long, the reaction steps are many, the amount of solvent used is large, and the potential for technological improvement is great.
In terms of influence, it is mainly to form its own characteristic products and increase the influence of the industry. It is understood that due to the severe homogeneity competition in my country's pharmaceutical intermediate industry, if companies can create their own superior products, they will certainly be able to gain an advantage in the market.
In terms of transformation, at present, as domestic environmental protection requirements become stricter, resources are tilted towards high value-added industries, and with the increase in environmental protection costs, transformation has become a problem that pharmaceutical intermediates companies have to think about for sustainable development.